<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03025087</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00046611</org_study_id>
    <nct_id>NCT03025087</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine and Cognitive Function After Surgery</brief_title>
  <official_title>Hydroxychloroquine and Cognitive Function After Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether hydroxychloroquine decreases the relative
      leakage of the brain barrier after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hydroxychloroquine will be administered preoperatively to 30 patients undergoing cardiac or
      noncardiac surgery. All patients will undergo magnetic resonance imaging (MRI) with
      gadolinium in the post-operative period before hospital discharge in order to assess blood
      brain barrier permeability.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of T1 relaxivity difference</measure>
    <time_frame>Postoperative day 2-5</time_frame>
    <description>Relative blood brain barrier leakage for the segmented regions of interest (cortex, diencephalon, hippocampus, cerebellum, global) will be expressed as the ratio of T1 relaxivity difference between the initial and final post-contrast maps divided by magnitude of the initial enhancement from baseline. All positive ratios represent a relative magnitude estimate of contrast retention in brain extracellular space.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Individuals Undergoing Cardiac and General Surgery</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 400 mg daily until the day of MRI imaging on postoperative day 2-5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 400 mg twice daily (800 mg total) until the day of MRI imaging on postoperative day 2-5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 500 mg twice daily (1000 mg total) until the day of MRI imaging on postoperative day 2-5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ 1-2 hours after separation from CPB or at end of noncardiac surgery followed by the highest tolerated dose from the previous 4 phases divided into 2 equal daily doses until the day of MRI imaging on postoperative day 2-5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Participants will be getting hydroxychloroquine</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_label>Phase 3</arm_group_label>
    <arm_group_label>Phase 4</arm_group_label>
    <arm_group_label>Phase 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, age â‰¥ 50 years old.

          2. Patients scheduled to undergo cardiac surgery (CABG, CABG + Valve, Valve) with CPB or
             general surgery (e.g. orthopedic, abdominal, urological).

          3. Patient has voluntarily signed and dated the study-specific informed consent form
             approved by Duke University Health System Institutional Review Board (DUHS IRB)

        Exclusion Criteria:

          1. Cardiac surgery scheduled to be performed without cardiopulmonary bypass

          2. Patients requiring emergent operation

          3. Patients with a history of myocardial infarction within 7 days of surgery

          4. Patients with a history of porphyria, psoriasis, chronic dermatitis, or retinal
             disease

          5. Patients receiving preoperative digoxin

          6. Patients with symptomatic cerebrovascular disease with substantial residual deficit

          7. Patients with a history of alcohol abuse within 2 years of screening

          8. Patients with history of psychiatric illness

          9. Patients with impaired liver and/or kidney functions (AST, ALT 2 times the upper limit
             of normal and/or serum creatinine of more than 2.0 mg/dl

         10. Patients with less than a 7th grade education or unable to read and thus unable
             complete the neuropsychological testing

         11. Patients scoring &lt; 26 on a baseline Mini Mental State examination (MMSE) or scoring
             &gt;27 on the Center for Epidemiological Studies - Depression (CES-D) scale

         12. Female subjects of childbearing potential who have had menstrual period within the
             past two years

         13. Patients with bodily implants unsafe for MRI use

         14. Patients with a history of claustrophobia

         15. Known or suspected hypersensitivity to quinine (chloroquine or hydroxychloroquine)

         16. Patient with pre-existing diagnosis of G6PD deficiency

         17. Patients who have participated in another interventional clinical study within the
             previous 30 days

         18. Any other concurrent disease or illness that, in the opinion of the investigator,
             makes the patient unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph P Mathew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiffany L Bisanar, RN, BSN</last_name>
    <phone>919-681-0866</phone>
    <email>tiffany.bisanar@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joseph P Mathew, MD</last_name>
    <phone>919-681-6646</phone>
    <email>joseph.mathew@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke Health</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Bisanar, RN, BSN</last_name>
      <phone>919-681-0866</phone>
      <email>tiffany.bisanar@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph P Mathew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2017</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

